FDA Panel To Weigh REMS For Jazz's Fibromyalgia Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Discussions on sodium oxybate likely to stray into effectiveness of current risk management measures for company's narcolepsy drug Xyrem, which contains the same active ingredient.
You may also be interested in...
PAH Market Heats Up: New Approvals For Actelion, United Therapeutics
With a Risk Evaluation and Mitigation Strategy for Tracleer now approved by FDA, Actelion can maximize the drug's selling potential across a broader range of pulmonary arterial hypertension patients before it faces generics in 2015
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.